Description

Established in 2015 and headquartered in Beijing, China, Beijing Airdoc Technology Co., Ltd. specializes in delivering artificial intelligence-driven solutions for early detection, diagnosis, and comprehensive health risk assessment. These innovative retina-based technologies serve both medical facilities and consumer healthcare providers across Mainland China and globally. Its core product line, Airdoc-AIFUNDUS, comprises AI-powered software medical devices designed for auxiliary diagnostics. Version 1.0 assists in diagnosing diabetic retinopathy, while Version 2.0 extends this capability to hypertensive retinopathy, retinal vein occlusion, and age-related macular degeneration. The comprehensive Version 3.0 provides aid in detecting a wide array of conditions, including pathological myopia, retinal detachment, glaucoma, cataracts, ICVD/ASCVD, gestational diabetic retinopathy, gestational hypertensive retinopathy, papilledema intracranial, hypertension retinopathy, and anemia. Beyond diagnostic software, the company also develops health risk assessment tools capable of identifying risk indicators for numerous lesions and diseases. These include conditions like hyperthyroidism, Graves' ophthalmopathy, retinal vein occlusion, dementia, Parkinson's disease, atrial fibrillation, and arteriosclerosis. These solutions are deployed across diverse healthcare settings, from health checkup centers and community clinics to insurance providers, optometry centers, and pharmacies. Additionally, Beijing Airdoc supplies complementary hardware, such as specialized fundus cameras.